Optimind Pharma Corp.
OMND
CNSX
| 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | 11/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -19.90% | -35.46% | -43.35% | -29.40% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -19.90% | -35.46% | -43.35% | -29.40% | -- |
| Cost of Revenue | -61.57% | -64.22% | -60.28% | -46.71% | -- |
| Gross Profit | 87.68% | 20.79% | 2.31% | 10.43% | -- |
| SG&A Expenses | -39.98% | -44.31% | -51.73% | -28.61% | -- |
| Depreciation & Amortization | -100.00% | -86.45% | -69.21% | -55.56% | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -52.50% | -53.78% | -57.34% | -20.89% | -- |
| Operating Income | 58.44% | 57.15% | 59.41% | 19.33% | -- |
| Income Before Tax | 66.25% | 65.48% | 67.43% | 54.95% | -- |
| Income Tax Expenses | -51.16% | -51.16% | -51.16% | 2.99% | -- |
| Earnings from Continuing Operations | 66.51% | 65.72% | 67.64% | 55.10% | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 66.51% | 65.72% | 67.64% | 55.10% | -- |
| EBIT | 58.44% | 57.15% | 59.41% | 19.33% | -- |
| EBITDA | 82.12% | 75.86% | 67.98% | 19.58% | -- |
| EPS Basic | 68.47% | 67.73% | 71.58% | 60.84% | -- |
| Normalized Basic EPS | 47.62% | 46.15% | 51.43% | 19.67% | -- |
| EPS Diluted | 68.47% | 67.73% | 71.58% | 60.84% | -- |
| Normalized Diluted EPS | 47.62% | 46.15% | 51.43% | 19.67% | -- |
| Average Basic Shares Outstanding | 12.33% | 10.42% | 15.97% | 21.31% | -- |
| Average Diluted Shares Outstanding | 12.33% | 10.42% | 15.97% | 21.31% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
